GenVec Receives Orphan Drug Designation, $22M Development Deal
GenVec’s experimental drug to treat pancreatic cancer has been granted orphan drug status by the U.S. Food and Drug Administration.
cancer
Micromet Signs $477M Deal with Sanofi-Aventis
Micromet has licensed one of its cancer-fighting antibody candidates to Sanofi-Aventis in a $477 million deal.
Ligand to Buy Struggling Metabasis
Ligand Pharmaceuticals has agreed to buy the struggling Metabasis Therapeutics for $3.2 million in cash.
FDA Calendar November Stocks: Turkeys or a Happy Thanksgiving?
On 10/19/09, BioElectronics (OTC: BIEL.PK) announced the initial results from the pilot section of its ongoing acetaminophen comparison study.
Interview with Jeffrey Davis, CEO of Access Pharmaceuticals
OneMedPlace recently interviewed CEO Jeffrey Davis about the Dallas-based company’s pipeline.
BioDelivery Sciences (NASDAQ: BDSI): Restarting the Catalyst Cycle
BDSI focuses on the niche market of pain management and supportive cancer care.
Onyx Pharmaceuticals to Acquire Proteolix
Onyx Pharmaceuticals has agreed to purchase private biotechnology company Proteolix for $276 million in cash.
Positive Phase II Data for Peregrine’s Lung Cancer Treatment
Peregrine Pharmaceuticals reported positive Phase II data in a clinical trial of bavituximab in patients with a deadly form of lung cancer.
Inovio Biomedical (AMEX: INO): A DNA Vaccine Delivery Innovator
Inovio Biomedical (AMEX: INO) is developing a robust pre-clinical and early clinical stage pipeline of innovative DNA-based vaccines and therapeutics that target cancer, influenza, and other infectious diseases (e.g. HIV) based on its SynCon DNA vaccine construct and electroporation DNA delivery technology platforms.
BioSante (NASDAQ: BPAX): LibiGel Provides Big Upside Potential
On 9/22/09, BioSante and Cell Genesys (NASDAQ: CEGE) announced that they have determined the final exchange ratio will be 0.1828 in connection with the previously announced merger between the companies.